Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300932 | 1.00 | CTSL (0.48) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL19839017 | 0.93 | FKBP1A (0.50) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL5181381 | 0.91 | HTR2C (0.49) | CTSLFKBP1AKLK7HTR2CHTT | |
| SCHEMBL22221127 | 0.88 | HTR2C (0.49) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL1300329 | 0.87 | FKBP1A (0.47) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL1300327 | 0.87 | FKBP1A (0.47) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL22221294 | 0.86 | FKBP1A (0.45) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL3727727 | 0.85 | FKBP1A (0.44) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL9608981 | 0.85 | FKBP1A (0.44) | CTSLFKBP1AKLK7HTR2CABCB1 | |
| SCHEMBL31486410 | 0.84 | DPP4 (0.44) | CTSLFKBP1AKLK7HTR2CABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20090131668-A1 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7498330-B2 | 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATORIES SERVIER (FR) | 2009-03-03 | — | — | US | disclosed |
| US-20050209234-A1 | 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2005-09-22 | — | — | US | disclosed |
| CN-1147489-C | New bicyclo aminopyrazineone compound, its producing process and medical composition containing them | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | CTSL 352/4885FKBP1A 617/4885KLK7 1646/4885 |
| US-20090131668-A1 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | F2, TBXA2R, PDGFRA | CTSL 1470/4885FKBP1A 1720/4885KLK7 3030/4885 |
| US-20050209234-A1 | 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | F2, TBXA2R, PDGFRA | CTSL 1470/4885FKBP1A 1720/4885KLK7 3030/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | CTSL 352/4885FKBP1A 617/4885KLK7 1646/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | CTSL 352/4885FKBP1A 617/4885KLK7 1646/4885 |
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | CTSL 99/4885FKBP1A 4076/4885KLK7 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.